Characterization of [125I]‐PD164333, an ETA selective non‐peptide radiolabelled antagonist, in normal and diseased human tissues

[1]  A. Doherty,et al.  Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists. , 1997, Journal of medicinal chemistry.

[2]  A. Davenport,et al.  Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  A. Davenport,et al.  Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. , 1996, Circulation research.

[4]  J. Mcculloch,et al.  Endothelin Receptor Antagonist Increases Cerebral Perfusion and Reduces Ischaemic Damage in Feline Focal Cerebral Ischaemia , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  L. Edvinsson,et al.  Endothelin-A and -B receptors in human coronary arteries and veins , 1996, Regulatory Peptides.

[6]  A. Davenport,et al.  Endothelin receptors in human coronary artery and aorta , 1996, British journal of pharmacology.

[7]  J. Barrish,et al.  Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity. , 1996, Biochemistry.

[8]  D. Webb,et al.  Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. , 1995, Circulation.

[9]  J. Keiser,et al.  Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist. , 1995, The Journal of pharmacology and experimental therapeutics.

[10]  A. Davenport,et al.  ETA receptor‐mediated constrictor responses to endothelin peptides in human blood vessels in vitro , 1995, British journal of pharmacology.

[11]  A. Doherty,et al.  Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. , 1995, Journal of medicinal chemistry.

[12]  C. Kanthou,et al.  The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[13]  A. Davenport,et al.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub‐type , 1995, British journal of pharmacology.

[14]  A. Davenport,et al.  Selectivity of [125I]‐PD 151242 for human, rat and porcine endothelin ETA receptors in the heart , 1995, British journal of pharmacology.

[15]  A. Davenport,et al.  [125I]‐PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature , 1994, British journal of pharmacology.

[16]  W. Bax,et al.  Different endothelin receptors involved in endothelin‐1‐ and sarafotoxin S6B‐induced contractions of the human isolated coronary artery , 1994, British journal of pharmacology.

[17]  A. Davenport,et al.  Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro , 1994, British journal of pharmacology.

[18]  L. Edvinsson,et al.  Endothelin-A receptors mediate contraction in human cerebral, meningeal and temporal arteries. , 1994, Journal of the autonomic nervous system.

[19]  K. Rabe,et al.  Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005. , 1994, European journal of pharmacology.

[20]  W. Neidhart,et al.  Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  J. D. Elliott,et al.  1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. , 1994, Journal of medicinal chemistry.

[22]  P. Vallance,et al.  Human saphenous vein contains both endothelin ETA and ETB contractile receptors. , 1994, European journal of pharmacology.

[23]  Y. Sugishita,et al.  Endothelin receptor subtypes in human versus rabbit pulmonary arteries. , 1994, Journal of applied physiology.

[24]  L. Edvinsson,et al.  Localization of Endothelin Immunoreactivity and Demonstration of Constrictory Endothelin-A Receptors in Human Coronary Arteries and Veins , 1994, Journal of cardiovascular pharmacology.

[25]  S. Sasayama,et al.  Endothelin-1-selective receptor in the arterial intima of patients with hypertension. , 1994, Hypertension.

[26]  L. V. von Segesser,et al.  Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. , 1994, Circulation.

[27]  P. Vallance,et al.  Endothelin receptors mediating functional responses in human small arteries and veins , 1994, British journal of pharmacology.

[28]  A. Doherty,et al.  [125I]‐PD 151242: a selective radioligand for human ETA receptors , 1994, British journal of pharmacology.

[29]  C. Johnston,et al.  EFFECTS OF CALCIUM‐ AND ETa‐RECEPTOR ANTAGONISTS ON ENDOTHELIN‐INDUCED VASOCONSTRICTION AND LEVELS OF ENDOTHELIN IN THE HUMAN INTERNAL MAMMARY ARTERY , 1994, Clinical and experimental pharmacology & physiology.

[30]  T. Godfraind.  Evidence for heterogeneity of endothelin receptor distribution in human coronary artery , 1993, British journal of pharmacology.

[31]  A. Davenport,et al.  Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. , 1992, Circulation research.

[32]  D. Stewart,et al.  Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery. , 1990, European journal of pharmacology.

[33]  A. Franco‐Cereceda,et al.  Endothelin‐ and neuropeptide Y‐induced vasoconstriction of human epicardial coronary arteries in vitro , 1989, British journal of pharmacology.

[34]  G A McPherson,et al.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. , 1985, Journal of pharmacological methods.

[35]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[36]  A. Taylor,et al.  Blocked ETA receptors prevent ischemia and reperfusion injury in rat lungs. , 1996, Journal of applied physiology.

[37]  A. Davenport,et al.  ETA Receptors Predominate in the Human Vasculature and Mediate Constriction , 1995, Journal of cardiovascular pharmacology.

[38]  A. Davenport,et al.  Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle. , 1993, Journal of cardiovascular pharmacology.